[Asia Economy Reporter Hyunseok Yoo] KPM Tech is on a continuous rise. It appears that the decision on the Nasdaq listing date of Humanigen, a U.S. company invested in by Telcon RF Pharmaceutical, has influenced this trend.
As of 1:29 PM on the 18th, KPM Tech was trading at 3,010 KRW, up 6.93% (195 KRW) compared to the previous trading day. This marks five consecutive days of gains since the 14th.
Humanigen announced on the 17th that it will be listed and start trading on the U.S. Nasdaq market from Friday, the 18th (U.S. local time). The stock ticker is ‘HGEN’.
Humanigen is a U.S. company developing various new drugs using its pipeline candidate Lenzilumab. It is currently conducting Phase 3 clinical trials in the U.S. for a COVID-19 treatment.
Meanwhile, in the recent public offering of 8 million common shares conducted for the listing, the price was set at $8.5 per share, and Humanigen is expected to raise approximately $68 million.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
